CLINICAL TRIAL: RAGE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项II期研究是一项双盲、安慰剂对照、随机化、多中心研究，旨在评价PF-04494700治疗18个月的疗效和安全性。随机分配至3个治疗组的受试者将分别接受20 mg、5 mg和安慰剂胶囊。该研究将招募约399名50岁或以上的参与者，并根据MMSE评分14-26分诊断为轻度至中度AD。霍华德大学的研究中心将招募并监测399名参与者中的15名。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This Phase 2 study is a double-blind, placebo-controlled, randomized, multicenter study evaluating the efficacy and safety of 18 months of treatment sith PF-04494700. Participants radomized to 3 treatment groups will receive 20mg, 5mg and placebo capsules respectively. The study will recruit approximately 399 participants that are 50 years or older and diagnosed with mild to moderate AD as will be indicated from MMSE scores of 14-26. The Howard University site will recruit and monitor 15 of the 399 particpants in the study.